NCT03959436

Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery

Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 612 (actual)
• Sponsor: Maisonneuve-Rosemont Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Carbetocin (Duratocin®) is a long-acting form of oxytocin, with a half-life almost 10 times longer. Studies have demonstrated that carbetocin diminishes the need for secondary uterotonic agents compared to oxytocin for cesarean delivery (CD). Despite certain Canadian guidelines recommending its use for elective CD, several Canadian centers and other countries have not adopted carbetocin. The purpose of this study is to prospectively gather electronic data on all CDs over a one year period, elective and emergent, in a single institution, and to evaluate the efficacy and other clinical outcomes when carbetocin is used as a first line uterotonic for all CDs. A database using Microsoft Dynamics CRM is available on smart phones and tablets. Data regarding additional uterotonic use and impact of carbetocin use during CD on intra and postoperative outcomes are gathered and analyzed. The primary outcome is the use of additional uterotonics in this population compared to that described in the literature for oxytocin as the primary uterotonic.

Conditions

• Carbetocin
• Cesarean Section Complications
• Uterotonics
• Uterine Atony With Hemorrhage

Interventions

Type	Name	Description
DRUG	Carbetocin	Carbetocin as the primary uterotonic for all cesarean sections

Timeline

• Start date: 2017-03-29
• Primary completion: 2018-03-16
• Completion: 2018-03-16
• First posted: 2019-05-22
• Last updated: 2019-05-29

Locations

1 site across 1 country: Canada